ArticleThe British journal of surgery2021
Centralized repeated resectability assessment of patients with colorectal liver metastases during first-line treatment: prospective study.
Article in The British journal of surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- The Geography of Liver Resection: Travel Distance, Facility Volume, and Access to Specialized Care in an Urban Setting.Annals of surgical oncology · 2026Article
- Real-world management of patients with simultaneously diagnosed synchronous liver and lung metastatic colorectal cancer - a national cohort study.Acta oncologica (Stockholm, Sweden) · 2026Article
- Antitumoral immunity induced by gel ethanol ablation to treat unresectable colorectal cancer metastases in the liver.PloS one · 2026Article
- Review
- Budget Impact of Shifting the Treatment Setting of Unresectable Liver Metastases Associated with Primary Colorectal Cancer Using Y-90 Resin Microspheres from the Outpatient Hospital to the Office-Based Laboratory.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Indications and outcomes of liver transplantation for liver tumors in the United States.Surgery in practice and science · 2024Article
- Liver Transplantation for Nonresectable Colorectal Liver Metastases (CRLM).Indian journal of surgical oncology · 2024Review
- Complete Blood Count Alterations Prior to the Diagnosis of Colorectal Cancer May Help in the Detection of Synchronous Liver Metastases.Journal of clinical medicine · 2023Article
- Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group.Annals of surgical oncology · 2023Article
- Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.The British journal of surgery · 2023Article
- Article
- Predicting early extrahepatic recurrence after local treatment of colorectal liver metastases.The British journal of surgery · 2023Article
- Sex differences in metastatic surgery following diagnosis of synchronous metastatic colorectal cancer.International journal of cancer · 2023Article
- Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues.Cancers · 2023Review
- Multimodal Management of Colorectal Liver Metastases: State of the Art.Oncology reviews · 2023Review
- Survival Study: International Multicentric Minimally Invasive Liver Resection for Colorectal Liver Metastases (SIMMILR-2).Cancers · 2022Article
- Hospital factors and metastatic surgery in colorectal cancer patients, a population-based cohort study.BMC cancer · 2022Article
- Observational
- Time to halt perioperative chemotherapy for resectable colorectal liver metastasis?The British journal of surgery · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastasectomy is probably underused in metastatic colorectal cancer. The aim of this study was to investigate the effect of centralized repeated assessment on resectability rate of liver metastases.
methodsThe prospective RAXO study was a nationwide study in Finland. Patients with treatable metastatic colorectal cancer at any site were eligible. This planned substudy included patients with baseline liver metastases between 2012 and 2018. Resectability was reassessed by the multidisciplinary team at Helsinki tertiary referral centre upfront and twice during first-line systemic therapy. Outcomes were resectability rates, management changes, and survival.
resultsOf 812 patients included, 301 (37.1 per cent) had liver-only metastases. Of these, tumours were categorized as upfront resectable in 161 (53.5 per cent), and became amenable to surgery during systemic treatment in 63 (20.9 per cent). Some 207 patients (68.7 per cent) eventually underwent liver resection or ablation. At baseline, a discrepancy in resectability between central and local judgement was noted for 102 patients (33.9 per cent). Median disease-free survival (DFS) after first resection was 20 months and overall survival (OS) 79 months. Median OS after diagnosis of metastatic colorectal cancer was 80, 32, and 21 months in R0-1 resection, R2/ablation, and non-resected groups, and 5-year OS rates were 68, 37, and 9 per cent, respectively. Liver and extrahepatic metastases were present in 511 patients. Of these, tumours in 72 patients (14.1 per cent) were categorized as upfront resectable, and 53 patients (10.4 per cent) became eligible for surgery. Eventually 110 patients (21.5 per cent) underwent liver resection or ablation. At baseline, a discrepancy between local and central resectability was noted for 116 patients (22.7 per cent). Median DFS from first resection was 7 months and median OS 55 months. Median OS after diagnosis of metastatic colorectal cancer was 79, 42, and 17 months in R0-1 resection, R2/ablation, and non-resected groups, with 5-year OS rates of 65, 39, and 2 per cent, respectively.
conclusionRepeated centralized resectability assessment in patients with colorectal liver metastases improved resection and survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.